Generics and Pharmaceuticals

Home/Publications/Health/Generics and Pharmaceuticals

Nearly one in three drugs found to have safety concerns after FDA approval

How often are safety concerns raised about a drug after it's been approved by the FDA? Nicholas Downing, MD, of the Department of Medicine at Brigham and Women's Hospital, and colleagues have found that for drugs approved between 2001 and 2010, nearly 1 in 3 had a postmarket safety event. The team defines postmarket safety

2017-05-11T07:48:11+00:00 Tags: |

Online pharmacies not requiring prescriptions could fuel antibiotic resistance

Scientists have found that antibiotics are illegally available without prescription on 45 per cent of online pharmacy websites surveyed, says study. The researchers from Imperial College London analysed 20 pharmacies that were available for UK citizens to access online. This is one of the few studies to have examined the online availability of antibiotics and

2017-02-21T10:43:05+00:00 Tags: |

World Trade Organization boosts poor countries’ ability to import generic drugs

Developing countries are expected to have greater access to generic pharmaceuticals under changes the World Trade Organization made in late January. WTO amended its intellectual property rules to allow developing countries that lack the infrastructure to produce generic drugs the ability to import the low-cost medicines under “compulsory licensing” arrangements. Compulsory licensing involves a government

2017-02-23T09:30:06+00:00

How the U.S. can beat hepatitis C: Don’t buy the pills, buy the company

In a recent article in Forbes, MIT Sloan School of Management visiting scientist Mark Trusheim and co-author Peter B. Bach, a physician at Memorial Sloan Kettering Cancer Center in New York, propose a startling response to the prevalence of hepatitis C and the high cost of the leading therapy: The U.S. government should not just

2017-02-23T09:32:41+00:00 Tags: , |

Generics are better for the country, but the choice isn’t easy

If you’ve stepped into a pharmacy recently, you know that getting sick is going to cost you. All of those insurance premiums and co-pays got you a doctor’s appointment and prescription; now you’re going to have to pay much more than someone in another developed nation to get the medication you need. According to data

These Cheap Paper Tests Could Fight Against The Huge Counterfeit Drug Problem

Counterfeit drugs are a big problem in the developing world. Up to 30% of medicines sold in parts of Africa, Latin America, and Asia are fakes, according to figures from the World Health Organization. And the consequences sometimes can be deadly. In Pakistan, in 2012, more than 100 heart patients died after taking faulty drugs

2017-01-21T13:52:37+00:00 Tags: |

Medicare Part D generic drug prices fall nearly 60% since 2010, GAO finds

A new US Government Accountability Office (GAO) report finds that prices for generic drugs in Medicare Part D fell 59% from the first quarter of 2010 to the second quarter of 2015. This report comes at a time when an increasing number of public policy experts, supply chain stakeholders, economists and others recognize that over

2017-01-21T13:52:37+00:00 Tags: |

Replacing big pharma’s products: how good are the generic options?

Big pharma and its big price tags have been the target for many a politician seeking to lower the cost of health care in the U.S. Martin Shkreli and his questionable big-pharma persona are an easy target and embodiment of how some continue to squeeze increasing profits out of America’s declining health. Drug prices have

2017-01-21T13:54:20+00:00

The Real Reason Big Pharma Wants to Help Pay for Your Prescription

This is not a feel-good story.  It’s a story about why expensive drugs  keep getting more expensive, and how U.S. taxpayers support a billion-dollar system in which charitable giving is, in effect, a very profitable form of investing for drug companies—one that may also be tax-deductible. Read more at  The Real Reason Big Pharma Wants to

2017-01-21T13:55:30+00:00

Toward a Nationwide HPV Vaccination Campaign in India

India is no stranger to initial resistance against vaccination campaigns, with both smallpox and polio eradication efforts only seeing success thanks to strong government efforts. Read more at   Toward a Nationwide HPV Vaccination Campaign in India | The Wire Cervical cancer, mainly caused by Human Papillomavirus infection, is the leading cancer in Indian women.  Learn

2017-01-21T13:56:01+00:00

The 3 deadliest drugs in America are all totally legal

As America debates drug policy reforms, there's one aspect of the war on drugs that remains perplexingly contradictory: Some of the most dangerous drugs in the US are legal.  Don't believe it?  The available data from the Centers for Disease Control and Prevention (CDC) shows these three legal drugs were responsible for more direct deaths in one

2017-01-21T13:56:05+00:00

This Pill Prevents HIV—But It’s Treated Like An Illicit Drug

Around the world, people have to jump through hoops, and sometimes break laws, just to get it.  We’re talking about Truvada, a name-brand pill that was approved in the United States in 2012, for individuals at higher risk of contracting HIV,  who take medication each day to reduce the likelihood that they’ll become infected if

2017-01-21T13:56:06+00:00

FDA Speeds Up Drug Approval Process to Help Avoid Future Price Gouging

The FDA can’t regulate drug prices, but is making an effort to prevent drug monopolies after Martin Shkreli’s action to hike Daraprim to $750 per pill. Source: FDA Speeds Up Drug Approval Process to Help Avoid Future Price Gouging Read more about price increases in the pharmaceutical industry in a Reuters report released April 5. Do more by

2017-01-21T13:56:39+00:00

GSK Won’t Seek Drug Patents In Poor Countries

GlaxoSmithKline will change its approach to patenting to make its medicines more affordable in developing countries. The pharmaceutical company says the move will cover about 85 countries and a combined population of more than 2 billion people. The move comes amid criticism that the industry's new drugs are too expensive for many people in Africa, Asia and

2017-01-21T13:56:40+00:00

What can be done to convince pharmaceutical firms to lower prescription drug prices?

When the news broke that Martin Shkreli, now the former CEO at Turing Pharmaceuticals, decided to increase the price of the life-saving drug, Daraprim, from $1,130 to $63,000, it made headlines all over the world. A price increase of more than 5,000 percent is probably not justified by high research and marketing costs. More likely

2017-01-21T13:56:40+00:00

Guardian Event: How does the pharmaceutical industry work with healthcare professionals?

Learn more about and register for a place at the Guardian's free event: Source: How does the pharmaceutical industry work with healthcare professionals? Event Read more about the pharmaceuticals industry at The Guardian's topic page. Do more by creating your own business plan for a pharmaceutical company. How do you manage research and development costs? Where does your

2017-01-21T13:56:41+00:00

Pharmaceutical drugs: How to stay unbiased and save patients money

The Everett Clinic made one simple change that is saving patients millions. Source: Pharmaceutical drugs: How to stay unbiased and save patients money | The Seattle Times Read more about generic vs. brand name drugs on the FDA's website. Do more by price comparing medicines on your next grocery trip. Which is more expensive: store branded pain

2017-01-21T13:56:42+00:00

Gilead Sovaldi Case Reveals Patent-Health Fissures In India

NEW DELHI — Are patient groups, health activists and manufacturers of low-cost generic drugs always on the same page? Do India’s generic companies think alike? The short answer: not necessarily. Source: Gilead Sovaldi Case Reveals Patent-Health Fissures In India Read more about the relationships between patents and generic drugs at News Medical. Do more by looking at

2017-01-21T13:57:20+00:00

India’s generic drugs crusader Dinesh Thakur drags pharma regulators to court

One of India's best-known whistleblowers, who exposed dangerous practices in the generic drug industry in 2013, is taking the country's drugs regulators to court, accusing them of failing to enforce rules on drug safety in the $15 billion industry. Read more from the source: India's generic drugs crusader Dinesh Thakur now drags pharma regulators to

2017-01-21T13:57:21+00:00